Tang, Hao
Bristol-Myers Squibb (United States)
3 papers on CoChatORCID 0000-0003-2202-0515
Most cited papers
- Verified
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 4,280
- Verified
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology
Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis
Cited by 407
- Verified
Use of in Vitro HTS-Derived Concentration–Response Data as Biological Descriptors Improves the Accuracy of QSAR Models of in Vivo Toxicity
Sedykh, A., Zhu, H., Tang, H., Zhang, L., Richard, A., Rusyn, I., & Tropsha, A. (2011) · Environmental Health Perspectives
Computational Drug Discovery MethodsAnimal testing and alternatives
Cited by 119
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free